Medical advancements reported for cystic fibrosis and chylomicronemia

Recent medical research and therapeutic developments in Germany highlight new advancements for rare genetic conditions.

Researchers from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health have studied the effects of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy on children with cystic fibrosis. Single-cell analyses indicate that within three months of starting ETI, certain epithelial cells in the airways show improved CFTR expression, innate immune pathways are partially reactivated, and inflammatory patterns in immune cells decrease.

In the field of lipid metabolism, the drug Plozasiran (marketed as Redemplo) has been introduced to treat Familial Chylomicronemia Syndrome (FCS). Approved by the European Medicines Agency, the drug targets the reduction of Apolipoprotein C3 (ApoC3) to effectively lower life-threatening triglyceride levels in adults. Concurrently, the Federal Joint Committee (G-BA) has initiated a procedure to adjust diagnostic requirements and drug guidelines to improve access to such specialized therapies.